ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "informatics"

  • Abstract Number: 1598 • ACR Convergence 2023

    Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis

    Chen-Yu Lee1, Caleb Marlin2, Xiaoping Yang1, Tayte Stephens2, Alessandra Ida Celia3, Jeff Hodgin4, Peter Izmirly5, H Michael Belmont6, Jill Buyon7, Chaim Putterman8, Judith James2, the Accelerating Medicines Partnership in RA/SLE9, Michelle Petri10, Joel Guthridge2, Avi Rosenberg11 and Andrea Fava1, 1Johns Hopkins University, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3John Hopkins University of Medicine, Rome, Italy, 4University of Michigan, Ann Arbor, MI, 5New York University School of Medicine, New York, NY, 6NYU School of Medicine, New York, NY, 7NYU Grossman School of Medicine, New York, NY, 8Albert Einstein College of Medicine, Bronx, NY, 9Multiple, Multiple, 10Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 11Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Lupus nephritis (LN) leads to end-stage kidney disease (ESKD) in more than 20% of patients despite optimal treatment. Up to 30% of LN patients…
  • Abstract Number: 1696 • ACR Convergence 2023

    Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

    Michael A. Smith1, Dominic Sinibaldi2, Saifur Rahman1, Chia-Chien Chiang2, Anna M. Hansen1, Jill Henault1, Carlos P. Roca3, Shu Wang1, Kamelia Zerrouki1, Rebecca Filippi1, Christopher Groves1, Zerai Manna4, Jun Chu4, Michael Davis4, sarthak gupta4, Christopher Morehouse1, Melissa De los Reyes1, Rachel Ettinger1, Roland Kolbeck1, Mariana Kaplan5, Miguel A. Sanjuan1, Richard M. Siegel6, sarfaraz Hasni4 and Kerry A. Casey1, 1BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Data Science and AI, AstraZeneca, Gaithersburg, MD, 3Data Science and AI, AstraZeneca, Cambridge, United Kingdom, 4Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 5Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, 6Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
  • Abstract Number: 1903 • ACR Convergence 2023

    Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry

    Katelyn Banschbach1, Jade Singleton2, Esi Morgan2 and Xing Wang3, 1University of Washington, Seattle, WA, 2Seattle Children's Hospital, Seattle, WA, 3Biostatistics Epidemiology and Analytics in Research (BEAR), Seattle Children’s Research Institute, Seattle, WA

    Background/Purpose: Research databases are missing 25-50% of race and ethnicity, typically related to Black and Hispanic data.1,2The absence of this data can lead to inaccurate…
  • Abstract Number: 1911 • ACR Convergence 2023

    Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study

    Catherine Nasrallah1, Cherish Wilson2, Alicia Hamblin1, Lindsay Jacobsohn1, Cammie Young3, Cammie Young3, Mary Nakamura4, Andrew Gross1, Judith Ashouri1, Mehrdad Matloubian1, Jinoos Yazdany1 and Gabriela Schmajuk2, 1University of California San Francisco, San Francisco, CA, 2UCSF / SFVA, San Francisco, CA, 3University of California San Francisco, Oakland, CA, 4UCSF/SFVAHCS, San Francisco, CA

    Background/Purpose: Improving shared decision-making using a treat-to-target approach, including the use of patient reported outcomes (PROs), is important to providing high quality care for rheumatoid…
  • Abstract Number: 2070 • ACR Convergence 2023

    Augmenting Medical Education: An Evaluation of GPT-4 and ChatGPT in Answering Rheumatology Questions from the Spanish Medical Licensing Examination

    Alfredo Madrid García1, zulema Rosales2, Dalifer Freites2, Inés Pérez Sancristóbal3, Benjamin Fernandez3 and Luis Rodríguez Rodríguez3, 1Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, 2Hospital Clínico San Carlos, Madrid, Spain, 3Hospital Clinico San Carlos, Madrid, Spain

    Background/Purpose: The emergence of Large Language Models (LLM) with remarkable performance such as GPT-4 and ChatGPT, has led to an unprecedented uptake in the population.…
  • Abstract Number: 2323 • ACR Convergence 2023

    An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health

    Yu Huang1, Lixia Yao2, zhengkang Fan3, Jingchuan Guo1 and Jiang Bian1, 1University of Florida, Gainesville, FL, 2Polygon Health Analytics LLC, Chalfont, PA, 3University of Florida, Gainsville, FL

    Background/Purpose: Systemic lupus erythematosus (SLE) has a relapsing-remitting course, with patients experiencing disease activity flares over time. Flares and prolonged disease activity are associated with…
  • Abstract Number: 2586 • ACR Convergence 2023

    A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis

    Peter C. Taylor1, Jenya Antonova2, Jennifer Geis3, Katharine Dilger3, David Chernoff4, Diana Abdueva3, Nancy Shadick5 and Michael Weinblatt6, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA, 3Aqtual Inc., Hayward, CA, 4Chernoff Consulting, Sausalito, CA, 5Brigham and Women's Hospital, Boston, MA, 6Harvard Medical School, Waban, MA

    Background/Purpose: Non-invasive differentiation of seropositive and seronegative rheumatoid arthritis (RA) from other conditions has been limited in the current practice. We aimed to evaluate the…
  • Abstract Number: 0163 • ACR Convergence 2023

    Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims

    Jing Li1, Julia Kay1, Sharon Abada1, Andriko Palmowski2, Rachael Stovall1, Jinoos Yazdany3 and Gabriela Schmajuk4, 1University of California San Francisco, San Francisco, CA, 2Charité - Universitätsmedizin Berlin, Berlin, Germany, 3University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA

    Background/Purpose: Understanding glucocorticoid (GC) exposure is critical for observational analyses in rheumatology. However, obtaining an accurate measure of GC exposure, including dosage and duration, has…
  • Abstract Number: 006 • 2023 Pediatric Rheumatology Symposium

    Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic

    Lauren Harper1, Alana Goldstein-Leever1, James Gallup1, Vidya Sivaraman2, Stacy Ardoin1, Kyla Driest1, Evan Mulvhihill3 and Alysha Taxter4, 1Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 3Nemours Children's Hospital, 4Nationwide Children's Hospital, Columbus, OH

    Background/Purpose: Patients with chronic rheumatic conditions, particularly lupus, have higher rates of depression, which significantly impacts their lives and can lead to poor medication compliance…
  • Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium

    Using the Electronic Health Record to Identify Subjects with Rheumatic Disease

    Alysha Taxter1, Matthew Basiaga2, Rajdeep Pooni3, Caitlan Pinotti4, Lisa Buckley5 and CARRA Registry Investigators6, 1Nationwide Children's Hospital, Columbus, OH, 2Mayo Clinic, Rochester, MN, 3Stanford University, Palo Alto, CA, 4Duke, Durham, NC, 5Vanderbilt University Medical Center, Nashville, TN, 6CARRA, Washington, DC

    Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
  • Abstract Number: 107 • 2023 Pediatric Rheumatology Symposium

    Validation of Serious Adverse Event Reporting in a Multicenter Registry

    Matthew Basiaga1, Rajdeep Pooni2, Caitlan Pinotti3, Lisa Buckley4, Alysha Taxter5 and CARRA Registry Investigators6, 1Mayo Clinic, Rochester, MN, 2Stanford University, Palo Alto, CA, 3Duke, Durham, NC, 4Vanderbilt University Medical Center, Nashville, TN, 5Nationwide Children's Hospital, Columbus, OH, 6CARRA, Washington, DC

    Background/Purpose: Children with rheumatic disease frequently require management with immune suppressing medications. The benefits of these interventions often outweigh the risks, however serious adverse events…
  • Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium

    Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis

    Alysha Taxter1, Marc Natter2, Min-Lee Chang2, Laura Schanberg3, Valarie Morrow4, Eveline Wu5, Tedryl Bumpass4, Alex Fist4, Meg Waite6, Vincent Del Gaizo7, Melanie Kohlheim7 and CARRA Registry Investigators7, 1Nationwide Children's Hospital, Columbus, OH, 2Boston Children's Hospital, Boston, MA, 3Duke University Medical Center, Durham, NC, 4Duke University, Durham, NC, 5UNC Chapel Hill, Chapel Hill, NC, 6Boston Children's Hospital, Boston, MA, 7CARRA, Washington, DC

    Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
  • Abstract Number: 1271 • ACR Convergence 2022

    Uptake of Rheumatology-Specific Quality Measures Submitted to National Pay-for-Performance Programs: An Analysis of Participants in the RISE Registry

    Emma Kersey1, Jing Li2, Zara Izadi1, Julia Adler-Milstein3, Tracy Johansson4, Jinoos Yazdany5 and Gabriela Schmajuk6, 1University of California San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF, San Francisco, 4American College of Rheumatology, Atlanta, GA, 5UCSF, San Francisco, CA, 6UCSF / SFVA, San Francisco, CA

    Background/Purpose: In recent years, the American College of Rheumatology has stewarded a number of rheumatology-specific quality measures for use in national pay-for-performance programs. While the…
  • Abstract Number: 1301 • ACR Convergence 2022

    Reliable Transition Policy Distribution and Transition Readiness Assessment Questionnaire Completion Using a Digital Intervention in a Pediatric Rheumatology Clinic

    Emily Smitherman1, Livie Huie1, John Bridges2, Randy Cron1, Victoria Gennaro3, Kim Jerkins1, Julie Mauldin1, Linda McAllister4, Annelle Reed3, Daniel Reiff1, Erica Reynolds3, Isabella Sanchez3, Carolyn Smith3, Matthew Stoll1, Tana Webb1, Peter Weiser1, JoAnne Zech1 and Melissa Mannion1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 3Children's of Alabama, Birmingham, AL, 4Children's of Alabama, Trussville, AL

    Background/Purpose: The process of transition from pediatric- to adult-based care should be well-timed, coordinated, and planned to educate and encourage the adolescent towards an adult…
  • Abstract Number: 1351 • ACR Convergence 2022

    Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study

    Cammie Young1, Anna Montgomery2, Catherine Nasrallah3, Lindsay Jacobsohn4, Jennifer Barton5, Sara Murray4, Jinoos Yazdany6 and Gabriela Schmajuk7, 1University of California San Francisco, San Francisco, CA, 2University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, 3UCSF, San Francisco, 4University of California, San Francisco, San Francisco, CA, 5VA Portland Health Care System/OHSU, Portland, OR, 6UCSF, San Francisco, CA, 7UCSF / SFVA, San Francisco, CA

    Background/Purpose: Shared decision making is a key component of a treat-to-target approach for the treatment of rheumatoid arthritis (RA). We created an EHR tool that…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology